A Study to Determine the Reliability of a Top Mount Actuation Indicator When Used With Levalbuterol Tartrate HFA MDI in Adult and Pediatric Subjects With Asthma or Chronic Obstructive Pulmonary Disease

NCT00583986 Phase 3 COMPLETED

This is a study to investigate the reliability, ruggedness and safety of the top mounted actuation indicator (TMAI) when used with Levalbuterol HFA MDI.

Details

Lead sponsor	Sumitomo Pharma America, Inc.
Phase	Phase 3
Status	COMPLETED
Enrolment	150
Start date	2005-09
Completion	2006-03

Conditions

• Asthma
• Chronic Obstructive Pulmonary Disease
• COPD

Interventions

• Levalbuterol HFA MDI with top mounted actuation indicator

Primary outcomes

• The difference between the number of actuations estimated via canister weight and the number of actuations recorded byt eh TMAI. — 10 weeks

Countries

United States